Navigation Links
Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
Date:5/9/2013

or 13. Use of Vectibix is not recommended for the treatment of colorectal cancer (CRC) with these mutations.

Important U.S. Product Safety Information
Vectibix is indicated as a single agent for the treatment of EGFR-expressing, mCRC with disease progression on or following fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens. The effectiveness of Vectibix as a single agent for the treatment of EGFR-expressing mCRC is based on progression-free survival. Currently, no data demonstrate an improvement in disease-related symptoms or increased survival with Vectibix.

Vectibix is not indicated for the treatment of patients with KRAS mutation-positive mCRC or for whom KRAS mCRC status is unknown.  Retrospective subset analyses of metastatic colorectal cancer trials have not shown a treatment benefit for Vectibix in patients whose tumors had KRAS mutations in codon 12 or 13.

WARNING: DERMATOLOGIC TOXICITY AND INFUSION REACTIONS
Dermatologic Toxicity: Dermatologic toxicities occurred in 89 percent of patients and were severe (NCI-CTC grade 3 or higher) in 12 percent of patients receiving Vectibix monotherapy. [See Dosage and Administration (2.1), Warnings and Precautions (5.1), and Adverse Reactions (6.1)].

Infusion Reactions: Severe infusion reactions occurred in approximately one percent of patients. Fatal infusion reactions occurred in post-marketing experience. [See Dosage and Administration (2.1), Warnings and Precautions (5.2), and Adverse Reactions (6.1, 6.3)].

The most common adverse reactions (≥ 20%) of Vectibix are skin rash with variable presentations, hypomagnesemia, paronychia, fatigue, abdominal pain, nausea and diarrhea, including diarrhea resulting in dehydration.

The most serious adverse reactions of Vectibix are pulmonary fibrosis, pulmonary embolism, severe dermatologic toxicity complicated by infectious sequelae and septic death, infusion reactions, abdominal pain,
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... N.J. , Sept. 17, 2014  Bayer HealthCare ... National Hemophilia Foundation,s 66 th Annual Meeting, which ... , D.C.  The data, which will be shared through ... treatment and patient care. Data will be presented in ... research into treatment modalities in hemophilia A patients, Bayer ...
(Date:9/17/2014)... , September 17, 2014 According ... by Component (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU), ... & Wellness), and by Geography - Global Forecast to ... electronics market is expected to reach $56.50 Billion by ... to 2020. Browse 235 market data Tables ...
(Date:9/17/2014)... CITY, Utah , Sept. 17, 2014 /PRNewswire/ ... an exclusive global licensing and collaboration agreement with ... and commercialize NuView,s investigative genomic-based diagnostic biomarker to ... agreement also includes all other future diagnostic-imaging applications. ... for in-vivo therapeutic delivery and in-vitro urine screen ...
Breaking Medicine Technology:Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5
... WORCESTER, Mass. and TORONTO, May 17, 2012  Generex ... today that new members have joined the Scientific ... Express, Inc. for the company,s AE37 breast cancer ... N. Hortobagyi, MD, FACP (University of Texas MD ...
... TUCSON, Ariz., May 17, 2012 SynCardia Systems, Inc. ... only FDA, Health Canada and CE (Europe) approved Total ... March 31, 2012, due in part to Certified Centers ... SynCardia temporary Total Artificial Heart . ...
Cached Medicine Technology:Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine 2Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine 3Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine 4SynCardia Posts Record Revenue and Profit in Q1 2012 2SynCardia Posts Record Revenue and Profit in Q1 2012 3
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Present-day ... groups of ancient humans, according to a new ... descended from indigenous hunter-gatherers and early European farmers. ... samples revealed they are also the descendants of ... genetic material from this third ancestral group, researchers ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... Diabetics and dieters who turn to artificial sweeteners to ... any favors, a new Israeli study suggests. Artificial ... containing no calories, researchers found in human and mouse ... to alter the bacteria residing in the intestines in ...
(Date:9/17/2014)... Research has shown that most 18-month-olds learn an ... however, little is known about how children process information ... preschool years. In a new study, a University of ... as they age, and a limit exists as to ... findings could help parents enhance their children,s vocabularies and ...
(Date:9/17/2014)... In a country where 77% of ... regular basis, how can Americans find healthy and fulfilling ... Stress Challenge , a 5-day interactive journey to putting ... From September 29th – October 3rd, the Hyland’s ... to specific topics that promote natural solutions for managing ...
(Date:9/17/2014)... Doheny HealthDay Reporter WEDNESDAY, ... beverage companies have made good on their pledge to cut ... The companies, acting together through the Healthy Weight Commitment Foundation, ... 2007 and 2012 and 1.5 trillion by 2015. They,ve actually ... collectively met their pledge and exceeded their pledge," said lead ...
Breaking Medicine News(10 mins):Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 2Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 3Health News:Babies learn words differently as they age, researcher finds 2Health News:Stress Less with the Hyland's 5-Day Stress Challenge 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 3
... in patients aged 80 and older, researchers say , ... questions the widespread use of implantable cardiac devices in ... in the hospital after receiving the devices. , Patients ... implantable defibrillators and pacemakers, even though most clinical trials ...
... no longer safe on the road , MONDAY, April ... input from family members are the most useful tools in ... or other dementia sets in, according to new guidelines from ... assessments are usually more accurate than the patient,s own opinion ...
... expert says , MONDAY, April 12 (HealthDay News) -- A ... in the blood raises the risk of heart disease for ... however, is not seen in men, according to the report, ... . , The study, by researchers at Italy,s National Cancer ...
... Important advances in the fight against cancer have come as ... were previously unknown to scientists. A new study led ... activate a viral infection that, paradoxically, can help anti-viral medications ... a team of UNC School of Medicine scientists and the ...
... In an ongoing effort to scientifically validate the age-old belief ... of patients, The University of Texas M. D. Anderson Cancer ... the efficacy of incorporating yoga into the treatment program of ... ever awarded by the National Cancer Institute for the study ...
... pain can go on too long and be ineffective, study ... that many patients with terminal cancer don,t benefit from getting ... symptoms like pain. , The researchers, who reported their findings ... Cancer , say doctors are failing to properly adjust treatments ...
Cached Medicine News:Health News:Study Questions Use of Heart Device Implants in the Very Old 2Health News:Docs Issue Guidelines for Drivers With Dementia 2Health News:Docs Issue Guidelines for Drivers With Dementia 3Health News:Simple Carbs Pose Heart Risk for Women 2Health News:Simple Carbs Pose Heart Risk for Women 3Health News:UNC study offers first clinical evidence of anti-cancer drug triggering viral infection 2Health News:M. D. Anderson receives 4.5 million grant, largest ever for study of yoga and cancer 2Health News:Many Terminal Cancer Patients May Be Overtreated 2
High sensitive, specific one step immunochromatographic assay for human infectious disease...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
Detection of Malarial antigen in Human whole blood....
The KAT-Quick Malaria test was designed for the diagnosis of Malaria, in laboratories, the home and for medical kits when travelling into malaria regions....
Medicine Products: